Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Trimethylamine N-oxide and related metabolites may regulate DNA methylation and trigger cardiovascular disease

Ma J, Lai CQ, Li XS, Wang M, Wang Z, Yao J, Guo X, Taylor KD, Lee S, Tracy RP, Peter D, Liu Y, Rotter[...]

Colliding crises: The global diabetes pandemic meets climate change-A scoping review

Perez JS, Hudson H, Araneta J, Bedell B, Aikins AD, Dugas LR, Eid M, Eshac Y, Fariduddin M, Fariduddin M, Jong K, Kapwata T, Luke[...]

The Potential of Chronic Hypoxia Biomarkers to Guide Home Oxygen Therapy Prescription in COPD

Lacasse Y, Maltais F, Casaburi R. The Potential of Chronic Hypoxia Biomarkers to Guide Home Oxygen Therapy Prescription in COPD. Respir Care. 2026 Jan;71(1):97-102. doi:[...]